Skip to main content

Table 3 Percentage of patients on monotherapy according to the biologic treatment

From: Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice

  1st Course 2nd Course 3rd Course 4th Course Total
N Patients on adalimumab monotherapy/patients on adalimumab (%) 5/27 (18) 2/3(67) - - 7/30 (23)
N patients on etanercept monotherapy/patients on etanercept (%) 12/39 (31) 4/6 (67) 1/1 (100) - 17/46 (37)
N patients on Infliximab monotherapy/patients on Infliximab (%) 0/7(0) 1/1 (100) 0/0 0/0 1/8 (12)
N patients on Abatacept monotherapy/patients on Abatacept (%) 1/1 (100) 6/10 (60) 0/3 (0) 1/1 (100) 8/15 (53)
N patients on Rituximab monotherapy/patients on Rituximab (%) 1/5 (20) 0/2 (0) 0/1 (0) 1/1 (100) 2/9 (22)
N patients on Tocilizumab monotherapy/patients on Tocilizumab (%) 0/0 (0) 2/2 (100) 3/4 (75) 0/0 (0) 5/6 (83)